103 related articles for article (PubMed ID: 22407148)
1. A unique MUC1-2-VNTR DNA vaccine suppresses tumor growth and prolongs survival in a murine multiple myeloma model.
Weng Y; Shao L; Ouyang H; Liu Y; Yao J; Yang H; Luo Y; Wang H; Zhao Z; Mou H; Zhou Z; Zhang Y
Oncol Rep; 2012 Jun; 27(6):1815-22. PubMed ID: 22407148
[TBL] [Abstract][Full Text] [Related]
2. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
[TBL] [Abstract][Full Text] [Related]
3. [MUC1-2VNTR DNA Vaccine Induces Immune Responses in Mouse Model with Multiple Myeloma].
Liu YB; Zhou ZP; Wang H; Yang H; Mu H; Huang GY; Zhang Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1366-9. PubMed ID: 26524039
[TBL] [Abstract][Full Text] [Related]
4. [Enhanced inhibitory effect of MUC1 gene vaccine on breast cancer growth by GM-CSF].
Yuan SF; Li KZ; Wang L; Yan Z; Han W; Zhang YQ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Nov; 20(6):737-40. PubMed ID: 15555449
[TBL] [Abstract][Full Text] [Related]
5. Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model.
Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Tezuka N; Sawai S; Inoue S; Fujino S; Maeda T; Itoh Y; Ogasawara K; Sato H; Ohkubo I; Kudo T
Cancer Gene Ther; 2002 Apr; 9(4):330-7. PubMed ID: 11960283
[TBL] [Abstract][Full Text] [Related]
6. Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect.
Liu C; Lu Z; Xie Y; Guo Q; Geng F; Sun B; Wu H; Yu B; Wu J; Zhang H; Yu X; Kong W
Immunol Lett; 2018 Aug; 200():33-42. PubMed ID: 29894719
[TBL] [Abstract][Full Text] [Related]
7. Effective anti-tumor responses induced by recombinant bacillus Calmette-Guérin vaccines based on different tandem repeats of MUC1 and GM-CSF.
Yuan S; Shi C; Han W; Ling R; Li N; Wang T
Eur J Cancer Prev; 2009 Sep; 18(5):416-23. PubMed ID: 19550341
[TBL] [Abstract][Full Text] [Related]
8. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
[TBL] [Abstract][Full Text] [Related]
9. Construction of a DNA vaccine encoding Flk-1 extracellular domain and C3d fusion gene and investigation of its suppressing effect on tumor growth.
Liang PH; Zhang KQ; Xu GL; Li YF; Wang LF; Nie ZL; Ye J; Wu G; Ge CG; Jin FS
Cancer Immunol Immunother; 2010 Jan; 59(1):93-101. PubMed ID: 19543726
[TBL] [Abstract][Full Text] [Related]
10. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice.
Snyder LA; Goletz TJ; Gunn GR; Shi FF; Harris MC; Cochlin K; McCauley C; McCarthy SG; Branigan PJ; Knight DM
Vaccine; 2006 Apr; 24(16):3340-52. PubMed ID: 16472547
[TBL] [Abstract][Full Text] [Related]
11. ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors.
Kovjazin R; Volovitz I; Kundel Y; Rosenbaum E; Medalia G; Horn G; Smorodinsky NI; Brenner B; Carmon L
Vaccine; 2011 Jun; 29(29-30):4676-86. PubMed ID: 21570434
[TBL] [Abstract][Full Text] [Related]
12. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
13. In vivo bioluminescence visualization of antitumor effects by human MUC1 vaccination.
Jeon YH; Choi Y; Kim HJ; Kang JH; Kim CW; Jeong JM; Lee DS; Chung JK
Mol Imaging; 2007; 6(5):297-303. PubMed ID: 18092514
[TBL] [Abstract][Full Text] [Related]
14. Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases.
Shi FF; Gunn GR; Snyder LA; Goletz TJ
Vaccine; 2007 Apr; 25(17):3338-46. PubMed ID: 17292519
[TBL] [Abstract][Full Text] [Related]
15. Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing.
Frøyland M; Ruffini PA; Thompson KM; Gedde-Dahl T; Fredriksen AB; Bogen B
Eur J Haematol; 2011 May; 86(5):385-95. PubMed ID: 21332794
[TBL] [Abstract][Full Text] [Related]
16. Immunization with two recombinant Bacillus Calmette-Guérin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice.
Yuan S; Shi C; Ling R; Wang T; Wang H; Han W
J Cancer Res Clin Oncol; 2010 Sep; 136(9):1359-67. PubMed ID: 20127358
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of double immunization of mice with mucin 1 and its coding DNA.
Mushenkova N; Moiseeva E; Chaadaeva A; Den Otter W; Svirshchevskaya E
Anticancer Res; 2005; 25(6B):3893-8. PubMed ID: 16309176
[TBL] [Abstract][Full Text] [Related]
18. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine.
Rong Y; Jin D; Wu W; Lou W; Wang D; Kuang T; Ni X; Qin X
BMC Cancer; 2009 Jun; 9():191. PubMed ID: 19534821
[TBL] [Abstract][Full Text] [Related]
19. Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity.
Li D; Li H; Zhang P; Wu X; Wei H; Wang L; Wan M; Deng P; Zhang Y; Wang J; Liu Y; Yu Y; Wang L
Eur J Immunol; 2006 May; 36(5):1324-36. PubMed ID: 16619287
[TBL] [Abstract][Full Text] [Related]
20. Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine.
Chung MA; Luo Y; O'Donnell M; Rodriguez C; Heber W; Sharma S; Chang HR
Cancer Res; 2003 Mar; 63(6):1280-7. PubMed ID: 12649188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
